Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Genotype-phenotype correlations in familial hypercholesterolemia].

K Kajinami1

  • 1Second Department of Internal Medicine, School of Medicine, Kanazawa University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 19, 2000
PubMed
Summary

Genetic mutations in the low-density lipoprotein (LDL) receptor gene cause familial hypercholesterolemia (FH). Identifying specific mutations can guide personalized FH treatment and management strategies for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease.

Clinical nephrology·2001
Same author

Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.

Clinical chemistry and laboratory medicine·2001
Same author

[Assay for LDL receptor activity].

Nihon rinsho. Japanese journal of clinical medicine·2001
Same author

[Atorvastatin].

Nihon rinsho. Japanese journal of clinical medicine·2001
Same author

Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.

Atherosclerosis·2001
Same author

NK-104: a novel synthetic HMG-CoA reductase inhibitor.

Expert opinion on investigational drugs·2000

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Familial hypercholesterolemia (FH) is caused by mutations in the low-density lipoprotein (LDL) receptor gene.
  • FH is characterized by elevated LDL cholesterol and early coronary artery disease.
  • Genetic heterogeneity of LDL receptor mutations contributes to varied clinical presentations of FH.

Purpose of the Study:

  • To identify LDL receptor gene mutations in 201 unrelated FH families in Japan.
  • To investigate the correlation between specific mutations and clinical manifestations.
  • To explore the development of more efficient mutation screening methods for FH.

Main Methods:

  • Molecular genetic analysis of the LDL receptor gene.
  • Identification of novel and known mutations in FH patients.

Related Experiment Videos

  • Comparison of therapeutic responses based on identified genotypes.

    • Main Results:

    • Eleven mutations (10 novel, 1 known) were identified in 201 FH families, explaining 38.8% of cases.
    • A mild FH type was identified, including homozygotes with longevity and normocholesterolemic heterozygotes, due to a 10 kb deletion (Tonami-2).
    • Cholesterol-lowering drug efficacy varied; P664L mutation (Kanazawa-2) heterozygotes responded better than those with a 6 kb deletion (Tonami-1).

    Conclusions:

    • The genetic heterogeneity of FH necessitates tailored patient management based on gene analysis.
    • Specific LDL receptor gene mutations influence FH severity and response to lipid-lowering therapies.
    • Further development of mutation screening is crucial for comprehensive FH diagnosis and care.